You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
博濟醫藥(300404.SZ)擬8000萬元在福田區建設博濟(福田)生物醫藥研發公共服務平台
格隆匯 03-02 20:01

格隆匯3月2日丨博濟醫藥(300404.SZ)公佈,近日,公司(“乙方”)與深圳市福田區科技創新局(“甲方”)共同簽署了《合作協議》,公司擬出資8000萬元在福田區建設博濟(福田)生物醫藥研發公共服務平台,並新註冊成立子公司負責建設運營。

甲方的承諾同意乙方生物醫藥研發公共服務平台入駐福田區國際生物醫藥產業園第三層,總面積約8,000平方米,以實際租賃面積為準,並給予租金支持。

乙方的承諾:乙方出資8000萬元在福田區成立的子公司負責平台的建設、裝修、招商以及運營管理工作,乙方持有其100%股權,且自完成登記註冊之日起五年內不遷出福田區。合作期間,乙方及其子公司應引進新藥、器械研發團隊(或上市許可持有人公司),引進的企業註冊地均須落户福田區。乙方子公司每年向甲方提交按甲方要求編制的年度工作報告,彙報項目運營情況、科研成果等內容。

此次投資是公司基於長期發展的戰略考量,資金來源為自有資金、自籌資金或其他合法資金來源,短期內對公司財務狀況及業績不會產生重大影響。此次公司入駐深圳福田區國際生物醫藥產業園,將有效藉助深圳的地域、經濟以及生物醫藥產業政策上的優勢,不斷提升公司在新藥研發領域的實力和影響力,符合公司的戰略發展需要。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account